The company's main products include AditxtScore, which allows individuals to understand and manage their immune profiles, and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that mimics the body's natural tolerance to its own tissues. Aditxt is also working on ADi products for organ transplantation, autoimmune diseases, and allergies. The company has license agreements with Loma Linda University and Leland Stanford Junior University. Aditxt, formerly known as ADiTx Therapeutics, was founded in 2017 and is headquartered in Richmond, Virginia.